Q1 2024 Delcath Systems Inc Earnings Call Transcript
Key Points
- Delcath Systems Inc (DCTH) reported US revenue for the first time, marking a significant milestone with $2 million from HEPZATO and $1.1 million from CHEMOSAT.
- The company has successfully activated six treatment centers and is engaged with over 30 centers at various stages of training and activation, showing progress in expanding its operational footprint.
- Delcath Systems Inc (DCTH) has achieved an effective gross margin of approximately 60% in the first quarter, indicating strong profitability potential as volumes increase.
- The establishment of a permanent J-Code effective April 1 has simplified the reimbursement process, enhancing the willingness of formulary committees to approve the use of the company's products.
- Delcath Systems Inc (DCTH) is supporting both internal and external efforts to add to the growing body of evidence that PHP procedure is an important treatment option for liver dominant cancers, indicating ongoing commitment to research and development.
- The company experienced technical difficulties during the earnings call, which may reflect on operational challenges or issues with event management.
- Delcath Systems Inc (DCTH) is still in the early stages of commercialization, and the long-term adoption and success of its treatments are not yet fully proven.
- The ramp-up of treatment centers and achieving consistent revenue from new centers may take longer than expected, as indicated by the current pace of center activations and treatments.
- While the company has reported initial success in reimbursement, the long-term sustainability of reimbursement rates and processes, especially with private payers, remains uncertain.
- Delcath Systems Inc (DCTH) is dependent on the successful training and certification of healthcare providers under the REMS program, which requires significant commitment and may impact the speed of scaling operations.
Good day, and welcome to the Delcath Systems first-quarter fiscal year 2024 financial results conference call. (Operator Instructions) Please note that this event is being recorded. I would now like to turn the conference over to David Hoffman, Delcath General Counsel. Please go ahead.
Thank you. And once again, welcome to Delcath Systems 2024 first-quarter earnings and business highlights call. With me on the call are Gerard Michel, Chief Executive Officer; Sandra Pennell, Senior Vice President of Finance; Kevin Muir, General Manager, Interventional Oncology; Vojo Vukovic, Chief Medical Officer; and Martha Rook, Chief Operating Officer.
I'd like to begin the call by reading the Safe Harbor statement. This statement is made pursuant to the Safe Harbor for forward-looking statements described in the Private Securities Litigation Reform Act of 1995. All statements made on this call with the exception of historical facts may be considered forward-looking
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
